Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | IL5 | P05113 | 1/20 | 0.40 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | CCR8 | P51685 | 2/20 | 0.34 |
| ▸ | WNT3A | P56704 | 9/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078326 | 0.85 | CYP2A6 (0.50) | CYP2A6CYP1A2IL5UHRF1CCR1 | |
| SCHEMBL17532790 | 0.81 | CYP1A2 (0.44) | CYP2A6CYP1A2IL5UHRF1CCR1 | |
| SCHEMBL17532781 | 0.79 | CYP2A6 (0.41) | CYP2A6CYP1A2IL5UHRF1MAOA | |
| SCHEMBL17051661 | 0.78 | CYP1A2 (0.56) | CYP2A6CYP1A2IL5UHRF1CCR1 | |
| SCHEMBL17532776 | 0.78 | CYP2A6 (0.47) | CYP2A6MAOAWNT3AHIPK2 | |
| SCHEMBL17532789 | 0.76 | CYP2A6 (0.50) | CYP2A6CYP1A2UHRF1MAOACCR1 | |
| SCHEMBL17532788 | 0.76 | CYP2A6 (0.39) | CYP2A6CYP1A2UHRF1MAOACCR1 | |
| SCHEMBL17532778 | 0.75 | CYP2A6 (0.40) | CYP2A6UHRF1MAOACCR1CCR5 | |
| SCHEMBL26873057 | 0.75 | CYP2A6 (0.53) | CYP2A6CYP1A2MAOACCR1CCR5 | |
| SCHEMBL14908371 | 0.74 | ROCK1 (0.47) | CYP2A6CYP1A2IL5UHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | AOC2, AZI2, KCNH2 | CYP2A6 3145/4885CYP1A2 978/4885IL5 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.